Examiner Cite

No

Initial*

Remove

Figures Appear

Pages.Columns.Lines where

Relevant Passages or Relevant

PTO/SB/08a (01-10)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Patent Number

Application Number		09758267
Filing Date		2001-01-12
First Named Inventor	Stefa	no Faccin et al.
Art Unit		2469
Examiner Name	Thai I	Nguyen
Attorney Docket Number		004770.01910

	1	5809424		1998-09	-15	Eizenhoefer				
If you wis	h to ac	d additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add	_
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite I	No Publication Number	Kind Publication Code ¹ Date		ition	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wis	h to ac	d additional U.S. Pub	lished Ap	plication	citatio	n information p	olease click the Ad	d butto	n. Add	
				FOREIG	3N PAT	TENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴		Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	Tn
	1	327605-1993	JP			1993-12-10	Wang, et al.			×
	2	170625-1998	JP			1998-06-26	Maeda, et al.			×
	3	304433-1998	JP			1998-11-13	Koise, et al.			×

U.S.PATENTS

Code¹ Issue Date

Name of Patentee or Applicant

of cited Document

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Art Unit
Examiner Name

Application Number		09758267
Filing Date		2001-01-12
First Named Inventor Stefar		no Faccin et al.
Art Unit		2469
Examiner Name	Thai f	Nguyen
Attorney Docket Number		004770 01910

	4	9916266	wo		1999-04-01	Forslow					
	5	1124556	CN		1996-06-12	Lindroos, et al.		×			
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add										
	NON-PATENT LITERATURE DOCUMENTS Remove										
Examiner Initials*	Examiner Cite Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city andor country where published.										
	1 Fourth Office Action in CN01813343 6 dated May 27, 2010.										
	2 International Search Report for PCT/IB01/00890 dated September 11, 2002. 3 Written Opinion for PCT/IB01/00890 dated November 29, 2002. 4 International Preliminary Examination Report for PCT/IB01/00890 dated January 21, 2003.										
	5	Communication in EP0193199739-1244 dated September 2, 2003.									
	6 Notice of Rejection Reasons for JP2001-541267 dated August 15, 2005. 7 Decision of Rejection for JP2001-586966 dated April 28, 2006.										

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09758267	
Filing Date		2001-01-12	
First Named Inventor Stefar		no Faccin et al.	
Art Unit		2469	
Examiner Name Thai I		vguyen	
Attorney Docket Number		004770.01910	

	8	2rd Ceneration Partnership Project, Technical Specification Group Services and System Aspects, 3G Charging, Call Event Data (3G TS 32.015, version 3.1.1, France, 3GPP Organizational Partners (ARIB, CWTS, ETSI, 11, TTA, TTC), March 2000	
	9	First Office Action in CN01813343.6 dated May 14, 2004,	×
	10	Second Office Action in CN01813343 6 dated October 29, 2004.	×
	11	Decision on Rejection in CN01913343 6 dated March 11, 2005.	×
	12	Notification of Third Office Action in CN01813343.6 dated November 28, 2008.	×
	13	Notice of Rejection Reasons (Summary) for JP2001-586906 dated August 11, 2005.	×
	14	Rejection Decision in CN01813343.6 dated July 4, 2011 with English translation.	×
	15	Notification of 6th Office Action in CN 01813343 6 dated February 22, 2011.	×
	16	Notification of Fifth Office Action of CN01813343.6 with English Translation dated October 11, 2010.	×
If you	wieh to s	Add	

EXAMINER SIGNATURE

Date Considered Examiner Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Application Number		09758267	
	Filing Date		2001-01-12	
INFORMATION DISCLOSURE	First Named Inventor	Stefar	no Faccin et al.	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		2469	
(Not for Submission under or of it 1.50)	Examiner Name	Thai f	vguyen	
	Attorney Docket Number		004770.01910	

See Risk Codes of USPTO Planto Documents at view USPTO, DOLL or MEPE P01.04. * Enter office and issued the occument, by the two letter code WIPO Standard ST3.3. ** For Legarance parted covaments, the includion of the paper of the region of the Engeror must provide the result invaries of the Engeror must provide the result invaries of the Engeror must provide the result invaries of the Standard ST3.0 ** Engelow the Engeror must provide the result invaries of the Standard ST3.0 ** Engelow the Standard ST3.0 ** En

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09758267
Filing Date		2001-01-12
First Named Inventor Stefa		no Faccin et al.
Art Unit		2469
Examiner Name Thai I		Nguyen
Attorney Docket Number		004770.01910

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.57(e)(2).

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith

Evan M. Clark

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

form of the signature.			
Signature	/Evan M. Clark/	Date (YYYY-MM-DD)	2012-08-24

Registration Number

64836

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. There will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operatment of Comments of December 1.00 and 1.00 Accessed, New York 1.00 Accessed, New York 1.00 Accessed, New York 1.00 Accessed, New York 1.00 Accessed 1.00

Name/Print

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95-79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) furnishing of the information solicited to isolutionary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan KORICs is to information, the U.S. Patient and Trademan KORICs may not be able to process and/or examine your submission, which may result in formation of proceedings or abandonment of the application or experigation of the patient.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S.C. 552a(m.).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations abant individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patient pursuant to 35 U.S. C. 151. Turther, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patient.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.